<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975117</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-0905-CU</org_study_id>
    <nct_id>NCT00975117</nct_id>
  </id_info>
  <brief_title>Spermotrend in the Treatment of Male Infertility</brief_title>
  <official_title>Assessment of the Efficacy of Dietary Supplement Spermotrend in the Treatment of Male Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of the dietary
      supplement Spermotrend improves spermatogenesis parameters in subjects with male infertility
      unrelated to major testicular conditions. The duration of this double-blind placebo
      controlled phase 3 clinical trial will be 24 weeks. The estimated number of males with
      infertility to be recruited and randomized for the study is 86.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parameters of seminal analysis at weeks 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization achievement</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of mild or severe adverse effects</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spermotrend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One Placebo tablet (Orally administered) twice a day, for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Spermotrend</intervention_name>
    <description>One Spermotrend tablet (Orally administered) twice a day, for 12 weeks</description>
    <arm_group_label>Spermotrend</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male infertility unrelated to major testicular conditions

          -  Must have at least one altered seminal parameter.

          -  Signed informed consent

        Exclusion Criteria:

          -  Hydrocele, varicocele, orchitis, epididymitis, irradiation or Chemotherapy.

          -  Previously treated and cured testicular condition.

          -  Non-transmissible chronic diseases

          -  Use of antioxidant agents within 6 months.

          -  Use of vitamins within 6 months.

          -  Use of anti-inflammatory drugs within 6 months.

          -  Use of hormones prescribed by an andrologist within 6 months

          -  Positive serology/HIV

          -  Leukocytospermia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Aguilar Charara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Ramón González Coro&quot; Gynecologic and Obstetric Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Ramón González Coro&quot; Gynecologic and Obstetric Hospital</name>
      <address>
        <city>Havana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>March 6, 2011</last_update_submitted>
  <last_update_submitted_qc>March 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Miguel Aguilar Charara</name_title>
    <organization>&quot;Ramón González Coro&quot; Gynecologic and Obstetric Hospital</organization>
  </responsible_party>
  <keyword>Dietary supplement</keyword>
  <keyword>male infertility</keyword>
  <keyword>spermatogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

